
    
      A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously
      and to investigate the pharmacokinetics of GSK221149A administered orally to healthy,
      pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks' gestation
    
  